Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Medicinal composition solution and preparation method and use thereof

A composition and drug technology, applied in the field of medicine, can solve problems such as degradation and difficult preparation, and achieve the effects of inhibiting lipid peroxidation, being difficult to degrade, and stabilizing exposure to light.

Inactive Publication Date: 2012-07-18
QINGDAO HUANGHAI PHARM CO LTD
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, Terisravone is insoluble or insoluble in water, so it is difficult to prepare injections containing Terisravone; at the same time, Terisravone contains structures that are easily oxidized, such as aromatic amines, and is very stable in a solid state, but its aqueous solution In contact with air, it is prone to oxidation-reduction reaction and degradation

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicinal composition solution and preparation method and use thereof
  • Medicinal composition solution and preparation method and use thereof
  • Medicinal composition solution and preparation method and use thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0025] In a nitrogen environment at 70°C, the antioxidant and L-arginine are dissolved in water according to the following weight ratio, and then Terisravone is added for dissolving to make Terreravone pharmaceutical composition solution, which The weight ratio is:

[0026] Teri Rabone 3g

[0027] L-Arginine 6g

[0028] Sodium thiosulfate 0.5g

[0029] Add water for pharmaceuticals to 1000ml

Embodiment 2

[0031] According to the following weight ratio:

[0032] Teri Rabone 3g

[0033] L-Arginine 6g

[0034] Sodium thiosulfate 0.5g

[0035] Add water for injection to 800ml

[0036] Add 0.5 g of sodium thiosulfate to 800 ml of water for injection at 80°C under nitrogen gas for 10 minutes, stir to dissolve, then add 6 g of L-arginine, and stir until completely dissolved. Add 3 g of Teriravone and stir until completely dissolved to obtain the pharmaceutical composition solution.

[0037] Add 1 g of activated carbon to the above-mentioned pharmaceutical composition solution, stir for 10 minutes, keep it at 70° C. for 20 minutes, and adjust the total amount to 1000 ml. The resulting solution was filtered with a membrane filter (0.45 μm in pore size) under a nitrogen atmosphere, and the pH was adjusted to 8.6 with hydrochloric acid. After the solution was clear and qualified, it was filled in an ampoule with a volume of 5 ml, replaced with nitrogen to remove air, and sterilized af...

Embodiment 3

[0044] According to the following weight ratio:

[0045] Teri Rabone 3g

[0046] L-Arginine 6g

[0047] Sodium thiosulfate 1g

[0048] Add water for injection to 800ml

[0049] Add 1.0 g of sodium thiosulfate to 800 ml of water for injection at 80° C. under nitrogen gas for 10 minutes, stir to dissolve, then add 6 g of L-arginine, and stir until completely dissolved. Add 3 g of Teriravone and stir until completely dissolved to obtain the pharmaceutical composition solution.

[0050] Add 1 g of activated carbon to the above pharmaceutical composition solution, stir for 10 minutes, keep it at 65° C. for 20 minutes, and adjust the total amount to 1000 ml. The resulting solution was filtered with a membrane filter (0.45 μm in pore size) under a nitrogen atmosphere, and the pH was adjusted to 8.6 with hydrochloric acid. After the solution was clear and qualified, it was filled in an ampoule with a volume of 5 ml, replaced with nitrogen to remove air, and sterilized after fusing...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to medicinal composition solution. The medicinal composition solution comprises 2-methy-5-imido-benzo-[d][1,3] oxazine [5-b] pyrazole, arginine, an antioxidant and a solvent, wherein the weight ratio of the 2-methy-5-imido-benzo-[d][1,3] oxazine [5-b] pyrazole, the arginine, the antioxidant to the solvent is 1:0.5 to 15:0.1 to 1.5:10 to 400; and the solvent is pharmaceuticalwater. The medicinal composition has high water dissolubility, and is difficult to degrade under the protection of the antioxidant. The medicinal composition solution has stable injection exposure, has stable effect of inhibiting coloring change, is not hemolytic, does not separate crystal in serum out and is safe to use.

Description

technical field [0001] The present invention relates to the field of medicine, in particular to a 2-methyl-5H-benzo[d]pyrazole[5,1-b][1,3]oxamate for the treatment of cerebral apoplexy, traumatic brain injury and traumatic shock. The pharmaceutical composition solution of oxazine-5 imine and its preparation method and application. Background technique [0002] The application number is 200910129816.3 Chinese patent application "2-methyl-5-imino-benzo [d] [1,3] oxazine [5-b] pyrazole compound and its preparation method and use" (hereinafter referred to as Teriravone) discloses a compound with brain neuroprotection, Terreravone has a strong ability to scavenge oxygen free radicals, alleviates free radical damage, and inhibits lipid peroxidation. Its effective dose is 3mg / kg. Terrebone as a raw material can significantly improve the neurological deficit symptoms of cerebral ischemia-reperfusion animals in a dose-dependent manner, reduce the size of cerebral infarction, reduc...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K9/08A61K31/5365A61K47/18A61K47/04A61P9/10A61P17/02A61P9/00A61P25/00A61P39/06
Inventor 李振霞苏国强徐晓琳曹瑞山王芳牛佰慧纪存朋
Owner QINGDAO HUANGHAI PHARM CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com